Consistent with this hypothesis was the study by Nie et al., where a de novo VEGFR2 inhibitor was combined with HT (40 min at 42 °C) in vitro in human umbilical vein endothelial cells (HUVECs), murine mammary cancer 4T1 cells, and murine colon carcinoma cells. The gene discussed is KDR; the disease is breast cancer.